Gilead Sciences has become the first biopharmaceutical company, which could develop a drug treatment to fight COVID-19, according to World Health Organization (WHO)
Gilead Sciences is a biopharmaceutical company focused on research, development, and commercialization of innovative medicines to improve care of patients suffering from life-threatening diseases. The company mostly focuses on treatments to HIV, AIDS, liver disease, and severe cardiovascular and respiratory diseases, which include Coronavirus.
The company's current success is permission to use its experimental drug treatment of Coronavirus. The USA allowed a procedure, which enables emergency treatment with unapproved drugs.
Gilead Sciences keeps developing treatment for HIV and is further progressing towards drug application to enhance immune function of a patient, which leads to viral remission and reduces patient's reactions in the absence of antiretroviral therapy.
Since the beginning of 2020, shares of the company gained more than 14 per cent. The main reason is drug treatment to fight COVID-19. Yet, similarly to other companies, Gilead Sciences has experienced decline due to investment spillovers in March. According to Alpho analysis, Gilead is not exception in current sentiments that make investors prefer less risky types of assets.
Main representatives of Gilead Sciences announced that HIV treatment remains the long-term goal for research and development efforts of the biopharmaceutical company.
